CoChat
Sign Up
Cited by 174Advanced Drug Delivery SystemsInhalation and Respiratory Drug DeliveryNanoparticle-Based Drug Delivery

Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations

Open access
Koo, Jain, Lim, Chaemin, Oh, Kyung Taek·2024·International Journal of Nanomedicine
DOI 10.2147/ijn.s439181PMC PMC10898487
Open this paper in CoChat — free accountOpen PDF

Abstract

Addressing disorders related to the central nervous system (CNS) remains a complex challenge because of the presence of the blood-brain barrier (BBB), which restricts the entry of external substances into the brain tissue. Consequently, finding ways to overcome the limited therapeutic effect imposed by the BBB has become a central goal in advancing delivery systems targeted to the brain. In this context, the intranasal route has emerged as a promising solution for delivering treatments directly from the nose to the brain through the olfactory and trigeminal nerve pathways and thus, bypassing the BBB. The use of lipid-based nanoparticles, including nano/microemulsions, liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, has shown promise in enhancing the efficiency of nose-to-brain delivery. These nanoparticles facilitate drug absorption from the nasal membrane. Additionally, the in situ gel (ISG) system has gained attention owing to its ability to extend the retention time of administered formulations within the nasal cavity. When combined with lipid-based nanoparticles, the ISG system creates a synergistic effect, further enhancing the overall effectiveness of brain-targeted delivery strategies. This comprehensive review provides a thorough investigation of intranasal administration. It delves into the strengths and limitations of this specific delivery route by considering the anatomical complexities and influential factors that play a role during dosing. Furthermore, this study introduces strategic approaches for incorporating nanoparticles and ISG delivery within the framework of intranasal applications. Finally, the review provides recent information on approved products and the clinical trial status of products related to intranasal administration, along with the inclusion of quality-by-design-related insights.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s439181

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 154

  1. [1]Kaushik A, Jayant RD, Bhardwaj V, Nair M. Personalized nanomedicine for CNS diseases. Drug Discovery Today. 2018; 23(5): 1007– 1015. doi: 10.1016/j.drudis.2017.11.010 29155026 PMC6897362 · DOI · Paper page
  2. [6]Patel AP, Fisher JL, Nichols E, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the global burden of disease Study 2016. Lancet Neurol. 2019; 18(4): 376– 393. doi: 10.1016/S1474-4422(18)30468-X 30797715 PMC6416167 · DOI
  3. [7]Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Cont Rel. 2018; 281: 139– 177. doi: 10.1016/j.jconrel.2018.05.011 29772289 · DOI · Paper page
  4. [8]Liu H-J, Xu P. Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. Advan Drug Del Rev. 2022; 191: 114619. doi: 10.1016/j.addr.2022.114619 PMC9724744 36372301 · DOI
  5. [9]Kapoor M, Cloyd JC, Siegel RA. A review of intranasal formulations for the treatment of seizure emergencies. Journal of Controlled Release. 2016; 237: 147– 159. doi: 10.1016/j.jconrel.2016.07.001 27397490 · DOI
  6. [10]Wong KH, Riaz MK, Xie Y, et al. Review of current strategies for delivering Alzheimer’s disease drugs across the blood-brain barrier. Internat J Mol Sci. 2019; 20(2): 381. doi: 10.3390/ijms20020381 PMC6358942 30658419 · DOI
  7. [11]Reddy S, Tatiparti K, Sau S, Iyer AK. Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors. Drug Discovery Today. 2021; 26(8): 1944– 1952. doi: 10.1016/j.drudis.2021.04.008 33865978 · DOI
  8. [12]Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Applied Materials Today. 2022; 29: 101631. doi: 10.1016/j.apmt.2022.101631 · DOI
  9. [13]Agrawal M, Saraf S, Saraf S, et al. Stimuli-responsive in situ gelling system for nose-to-brain drug delivery. J Cont Rel. 2020; 327: 235– 265. doi: 10.1016/j.jconrel.2020.07.044 32739524 · DOI
  10. [14]Akel H, Ismail R, Csoka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease. Europ J Pharmaceut Biopharmac. 2020; 148: 38– 53. doi: 10.1016/j.ejpb.2019.12.014 31926222 · DOI
  11. [15]Sabir F, Ismail R, Csoka I. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discovery Today. 2020; 25(1): 185– 194. doi: 10.1016/j.drudis.2019.10.005 31629966 · DOI
  12. [16]Feng Y, He H, Li F, Lu Y, Qi J, Wu W. An update on the role of nanovehicles in nose-to-brain drug delivery. Drug Discovery Today. 2018; 23(5): 1079– 1088. doi: 10.1016/j.drudis.2018.01.005 29330120 · DOI
  13. [18]Pardridge WM. Treatment of Alzheimer’s disease and blood-brain barrier drug delivery. Pharmaceuticals. 2020; 13(11): 394. doi: 10.3390/ph13110394 33207605 PMC7697739 · DOI
  14. [19]Delhaas E, Huygen F. Complications associated with intrathecal drug delivery systems. BJA Educ. 2020; 20(2): 51– 57. doi: 10.1016/j.bjae.2019.11.002 33456930 PMC7807963 · DOI
  15. [20]Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021; 20(5): 362– 383. doi: 10.1038/s41573-021-00139-y 33649582 · DOI · Paper page
  16. [21]Costa CP, Moreira JN, Lobo JMS, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharmac Sinica B. 2021; 11(4): 925– 940. doi: 10.1016/j.apsb.2021.02.012 PMC8105874 33996407 · DOI
  17. [22]Dkhar LK, Bartley J, White D, Seyfoddin A. Intranasal drug delivery devices and interventions associated with post-operative endoscopic sinus surgery. Pharmac Develop Technol. 2018; 23(3): 282– 294. doi: 10.1080/10837450.2017.1389956 28994339 · DOI
  18. [23]Goel H, Kalra V, Verma SK, Dubey SK, Tiwary AK. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: feats & fallacies. J Control Rel. 2022; 341: 782– 811. doi: 10.1016/j.jconrel.2021.12.009 34906605 · DOI
  19. [24]Dogan R, Senturk E, Ozturan O, Yildirim YS, Tugrul S, Hafiz AM. Conchal contractility after inferior turbinate hypertrophy treatment: a prospective, randomized clinical trial. Am J Otolaryngol. 2017; 38(6): 678– 682. 28844494
  20. [25]Jeong S-H, Jang J-H, Lee Y-B. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharmac Invest. 2023; 53(1): 119– 152. doi: 10.1007/s40005-022-00589-5 PMC9308891 35910081 · DOI
  21. [26]Crowe TP, Hsu WH. Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics. 2022; 14(3): 629. doi: 10.3390/pharmaceutics14030629 35336004 PMC8950509 · DOI
  22. [27]Vincent AJ, West AK, Chuah MI. Morphological and functional plasticity of olfactory ensheathing cells. J Neurocytol. 2005; 34(1–2): 65– 80. doi: 10.1007/s11068-005-5048-6 16374710 · DOI
  23. [28]Inoue D, Furubayashi T, Tanaka A, Sakane T, Sugano K. Effect of cerebrospinal fluid circulation on nose-to-brain direct delivery and distribution of caffeine in rats. Molec Pharmaceut. 2020; 17(11): 4067– 4076. doi: 10.1021/acs.molpharmaceut.0c00495 32955898 · DOI
  24. [29]Fukuda M, Kanazawa T, Iioka S, et al. Quantitative analysis of inulin distribution in the brain focused on nose-to-brain route via olfactory epithelium by reverse esophageal cannulation. Journal of Controlled Release. 2021; 332: 493– 501. doi: 10.1016/j.jconrel.2021.02.024 33647429 · DOI
  25. [30]Tashima T. Shortcut approaches to substance delivery into the brain based on intranasal administration using nanodelivery strategies for insulin. Molecules. 2020; 25(21): 5188. doi: 10.3390/molecules25215188 33171799 PMC7664636 · DOI
  26. [32]Costa C, Moreira J, Amaral M, Lobo JS, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Cont Rel. 2019; 295: 187– 200. doi: 10.1016/j.jconrel.2018.12.049 30610952 · DOI
  27. [33]Cone RA. Barrier properties of mucus. Advan Drug Deliv Rev. 2009; 61(2): 75– 85. doi: 10.1016/j.addr.2008.09.008 19135107 · DOI
  28. [34]Froehlich E, Roblegg E. Mucus as barrier for drug delivery by nanoparticles. J Nanosci Nanotechnol. 2014; 14(1): 126– 136. doi: 10.1166/jnn.2014.9015 24730255 · DOI
  29. [35]Wu L, Shan W, Zhang Z, Huang Y. Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties. Advan Drug Deliv Rev. 2018; 124: 150– 163. doi: 10.1016/j.addr.2017.10.001 28989056 · DOI
  30. [36]Patel AA, Patel RJ, Patel SR. Nanomedicine for intranasal delivery to improve brain uptake. Curr Drug Deliv. 2018; 15(4): 461– 469. doi: 10.2174/1567201814666171013150534 29034836 · DOI
  31. [37]Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discovery Today. 2002; 7(18): 967– 975. doi: 10.1016/S1359-6446(02)02452-2 12546871 · DOI
  32. [38]Kaur P, Garg T, Rath G, Goyal AK. In situ nasal gel drug delivery: a novel approach for brain targeting through the mucosal membrane. Artif Cells Nanomed Biotechnol. 2016; 44(4): 1167– 1176. doi: 10.3109/21691401.2015.1012260 25749276 · DOI
  33. [39]Jain H, Prabhakar B, Shende P. Modulation of olfactory area for effective transportation of actives in CNS disorders. J Drug Deliv Sci Technol. 2022; 68: 103091. doi: 10.1016/j.jddst.2021.103091 · DOI
  34. [40]Warnken ZN, Smyth HD, Watts AB, Weitman S, Kuhn JG, Williams RO. Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol. 2016; 35: 213– 222. doi: 10.1016/j.jddst.2016.05.003 · DOI
  35. [41]Xu J, Tao J, Wang J. Design and application in delivery system of intranasal antidepressants. Front Bioeng Biotechnol. 2020; 8: 626882. doi: 10.3389/fbioe.2020.626882 33409272 PMC7779764 · DOI
  36. [42]Sánchez-Dengra B, González-Álvarez I, Bermejo M, González-Álvarez M. Access to the CNS: strategies to overcome the BBB. Internat J Pharmac. 2023; 636: 122759. doi: 10.1016/j.ijpharm.2023.122759 36801479 · DOI
  37. [43]Pandit R, Chen L, Götz J. The blood-brain barrier: physiology and strategies for drug delivery. Advan Drug Deliv Rev. 2020; 165–166: 1– 14. doi: 10.1016/j.addr.2019.11.009 31790711 · DOI · Paper page
  38. [44]Mitusova K, Peltek OO, Karpov TE, Muslimov AR, Zyuzin MV, Timin AS. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnol. 2022; 20(1): 412. PMC9479308 36109754
  39. [45]Correia A, Monteiro A, Silva R, Moreira J, Lobo JS, Silva A. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders. Advan Drug Deliv Rev. 2022; 189: 114485. doi: 10.1016/j.addr.2022.114485 35970274 · DOI
  40. [46]Nguyen TT, Nguyen TTD, Tran N, Van Vo G. Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders. Neuroch Res. 2022; 2022: 1– 22. 34800247
  41. [47]Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Cont Rel. 2018; 270: 89– 100. doi: 10.1016/j.jconrel.2017.11.047 29199063 · DOI · Paper page
  42. [48]Shah D, Guo Y, Ban I, Shao J. Intranasal delivery of insulin by self-emulsified nanoemulsion system: in vitro and in vivo studies. Internat J Pharmac. 2022; 616: 121565. doi: 10.1016/j.ijpharm.2022.121565 35150847 · DOI
  43. [49]Jiang Y, Liu C, Zhai W, Zhuang N, Han T, Ding Z. The optimization design of lactoferrin loaded Hup A nanoemulsion for targeted drug transport via intranasal route. Internat J Nanomed. 2019; Volume 14: 9217– 9234. doi: 10.2147/IJN.S214657 PMC6885571 31819426 · DOI
  44. [50]Kaur A, Nigam K, Bhatnagar I, et al. Treatment of Alzheimer’s disease using donepezil nanoemulsion: an intranasal approach. Drug Deliv Translat Res. 2020; 10(6): 1862– 1875. doi: 10.1007/s13346-020-00754-z 32297166 · DOI
  45. [51]Mallick A, Gupta A, Hussain A, et al. Intranasal delivery of gabapentin loaded optimized nanoemulsion for augmented permeation. J Drug Deliv Sci Technol. 2020; 56: 101606. doi: 10.1016/j.jddst.2020.101606 · DOI
  46. [52]Arora A, Kumar S, Ali J, Baboota S. Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington’s disease: pharmacokinetic and brain delivery study. Chem Phys Lip. 2020; 230: 104917. doi: 10.1016/j.chemphyslip.2020.104917 32439327 · DOI
  47. [53]Ashhar MU, Kumar S, Ali J, Baboota S. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-Parkinson effect. Chem Phys Lip. 2021; 235: 105035. doi: 10.1016/j.chemphyslip.2020.105035 33400967 · DOI
  48. [54]Gaba B, Khan T, Haider MF, et al. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson’s disease model. BioMed Res Internat. 2019; 2019: 1– 20. doi: 10.1155/2019/2382563 PMC6487130 31111044 · DOI
  49. [55]Diedrich C, Zittlau IC, Machado CS, et al. Mucoadhesive nanoemulsion enhances brain bioavailability of luteolin after intranasal administration and induces apoptosis to SH-SY5Y neuroblastoma cells. Internat J Pharmac. 2022; 626: 122142. doi: 10.1016/j.ijpharm.2022.122142 36064075 · DOI
  50. [56]Fachel FNS, Medeiros-Neves B, Dal Prá M, et al. Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery-in vitro studies. Carbohy Pol. 2018; 199: 572– 582. doi: 10.1016/j.carbpol.2018.07.054 30143164 · DOI
  51. [57]Ahmad N, Ahmad R, Amir M, et al. Ischemic brain treated with 6-gingerol loaded mucoadhesive nanoemulsion via intranasal delivery and their comparative pharmacokinetic effect in brain. J Drug Deliv Sci Technol. 2021; 61: 102130. doi: 10.1016/j.jddst.2020.102130 · DOI
  52. [58]Patel RJ, Parikh RH. Intranasal delivery of topiramate nanoemulsion: pharmacodynamic, pharmacokinetic and brain uptake studies. Internat J Pharmac. 2020; 585: 119486. doi: 10.1016/j.ijpharm.2020.119486 32502686 · DOI
  53. [59]Kaur A, Nigam K, Srivastava S, Tyagi A, Dang S. Memantine nanoemulsion: a new approach to treat Alzheimer’s disease. J Microencapsul. 2020; 37(5): 355– 365. doi: 10.1080/02652048.2020.1756971 32293915 · DOI
  54. [60]Iqbal R, Ahmed S, Jain GK, Vohora D. Design and development of letrozole nanoemulsion: a comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Internat J Pharmac. 2019; 565: 20– 32. doi: 10.1016/j.ijpharm.2019.04.076 31051232 · DOI
  55. [61]Shen X, Cui Z, Wei Y, et al. Exploring the potential to enhance drug distribution in the brain subregion via intranasal delivery of nanoemulsion in combination with borneol as a guider. As J Pharmac Sci. 2023; 18(6): 100778. doi: 10.1016/j.ajps.2023.100778 PMC10711392 38089837 · DOI
  56. [62]Nogueira C, Lemos-Senna E, da Silva Vieira E, et al. β-caryophyllene cationic nanoemulsion for intranasal delivery and treatment of epilepsy: development and in vivo evaluation of anticonvulsant activity. J Nanopart Res. 2023; 25(1): 19. doi: 10.1007/s11051-023-05668-8 · DOI
  57. [63]Kurano T, Kanazawa T, Ooba A, et al. Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties. J Cont Rel. 2022; 344: 225– 234. doi: 10.1016/j.jconrel.2022.03.017 35296406 · DOI
  58. [64]Barros C, Aranha N, Severino P, et al. Quality by design approach for the development of liposome carrying ghrelin for intranasal administration. Pharmaceutics. 2021; 13(5): 686. doi: 10.3390/pharmaceutics13050686 34068793 PMC8151022 · DOI
  59. [65]Pashirova TN, Zueva IV, Petrov KA, et al. Mixed cationic liposomes for brain delivery of drugs by the intranasal route: the acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Coll Surf B. 2018; 171: 358– 367. doi: 10.1016/j.colsurfb.2018.07.049 30059851 · DOI
  60. [66]Katona G, Sabir F, Sipos B, et al. Development of lomustine and n-propyl gallate co-encapsulated liposomes for targeting glioblastoma multiforme via intranasal administration. Pharmaceutics. 2022; 14(3): 631. doi: 10.3390/pharmaceutics14030631 35336006 PMC8950329 · DOI
  61. [67]Sabir F, Katona G, Pallagi E, et al. Quality-by-design-based development of n-propyl-gallate-loaded hyaluronic-acid-coated liposomes for intranasal administration. Molecules. 2021; 26(5): 1429. doi: 10.3390/molecules26051429 33800788 PMC7961673 · DOI
  62. [68]Saka R, Chella N, Khan W. Development of imatinib mesylate-loaded liposomes for nose to brain delivery: in vitro and in vivo evaluation. AAPS Pharm Sci Tech. 2021; 22(5): 192. doi: 10.1208/s12249-021-02072-0 34184160 · DOI
  63. [69]Singh V, Krishan P, Shri R. Amelioration of ischaemia reperfusion-induced cerebral injury in mice by liposomes containing Allium cepa fraction administered intranasally. Artif Cells Nanomed Biotechnol. 2018; 46(sup3): 982– 992. doi: 10.1080/21691401.2018.1523181 30449174 · DOI
  64. [70]Yuwanda A, Surini S, Harahap Y, Jufri M. Study of valproic acid liposomes for delivery into the brain through an intranasal route. Heliyon. 2022; 8(3): e09030. doi: 10.1016/j.heliyon.2022.e09030 35284670 PMC8914119 · DOI
  65. [71]Taha MS, Kutlehria S, D’Souza A, Bleier BS, Amiji MM. Topical administration of verapamil in poly (ethylene glycol)-modified liposomes for enhanced sinonasal tissue residence in chronic rhinosinusitis: ex vivo and in vivo evaluations. Molecu Pharmaceut. 2023; 20(3): 1729– 1736. doi: 10.1021/acs.molpharmaceut.2c00943 PMC10629233 36744718 · DOI
  66. [72]Trapani A, De Giglio E, Cometa S, et al. Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: a comparative study. Europ J Pharmac Biopharm. 2021; 167: 189– 200. doi: 10.1016/j.ejpb.2021.07.015 34333085 · DOI
  67. [73]Wang L, Zhao X, Du J, Liu M, Feng J, Hu K. Improved brain delivery of pueraria flavones via intranasal administration of borneol-modified solid lipid nanoparticles. Nanomedicine. 2019; 14(16): 2105– 2119. doi: 10.2217/nnm-2018-0417 31397219 · DOI
  68. [74]Hasan N, Imran M, Kesharwani P, et al. Intranasal delivery of naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Internat J Pharmac. 2021; 599: 120428. doi: 10.1016/j.ijpharm.2021.120428 33662465 · DOI
  69. [75]Said DE, Amer EI, Sheta E, Makled S, Arafa FM, Diab HE. Nano-encapsulated antioxidant: retinoic acid as a natural mucosal adjuvant for intranasal immunization against chronic experimental toxoplasmosis. Trop Med Infect Dis. 2023; 8(2): 106. doi: 10.3390/tropicalmed8020106 36828522 PMC9962073 · DOI
  70. [76]Arora D, Bhatt S, Kumar M, et al. QbD-based rivastigmine tartrate loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer’s therapeutics. Frontiers in Aging Neuroscience. 2022; 2022: 869. PMC9407039 36034142
  71. [77]Yasir M, Sara UVS, Chauhan I, et al. Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol. 2018; 46(8): 1838– 1851.
  72. [78]Kataria I, Shende P. Nose-to-brain lipid nanocarriers: an active transportation across BBB in migraine management. Chemist Phys Lip. 2022; 243: 105177. doi: 10.1016/j.chemphyslip.2022.105177 35122739 · DOI
  73. [79]Yasir M, Chauhan I, Zafar A, et al. Glyceryl behenate-based solid lipid nanoparticles as a carrier of haloperidol for nose to brain delivery: formulation development, in-vitro, and in-vivo evaluation. Brazil J Pharmaceut Sci. 2023; 2023: 58.
  74. [80]Yasir M, Chauhan I, Zafar A, et al. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J Drug Deliv Sci Technol. 2021; 61: 102164. doi: 10.1016/j.jddst.2020.102164 · DOI
  75. [81]Trapani A, Guerra L, Corbo F, et al. Cyto/biocompatibility of dopamine combined with the antioxidant grape seed-derived polyphenol compounds in solid lipid nanoparticles. Molecules. 2021; 26(4): 916. doi: 10.3390/molecules26040916 33572331 PMC7916151 · DOI
  76. [82]Costa C, Cunha S, Moreira J, et al. Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: toxicological effect of surface charge on human neuronal cells. Internat J Pharmac. 2021; 607: 120933. doi: 10.1016/j.ijpharm.2021.120933 34324988 · DOI
  77. [83]Patel HP, Gandhi PA, Chaudhari PS, et al. Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: optimization and in vivo pharmacokinetic studies. J Drug Deliv Sci Technol. 2021; 64: 102533. doi: 10.1016/j.jddst.2021.102533 · DOI
  78. [84]Masjedi M, Azadi A, Heidari R, Mohammadi-Samani S. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. J Pharm Pharmacol. 2020; 72(10): 1341– 1351. doi: 10.1111/jphp.13316 32579251 · DOI
  79. [85]Nair SC, Vinayan KP, Mangalathillam S. Nose to brain delivery of phenytoin sodium loaded nano lipid carriers: formulation, drug release, permeation and in vivo pharmacokinetic studies. Pharmaceutics. 2021; 13(10): 1640. doi: 10.3390/pharmaceutics13101640 34683933 PMC8540129 · DOI
  80. [86]Torres J, Pereira JM, Marques-Oliveira R, et al. An in vitro evaluation of the potential neuroprotective effects of intranasal lipid nanoparticles containing astaxanthin obtained from different sources: comparative studies. Pharmaceutics. 2023; 15(4): 1035. doi: 10.3390/pharmaceutics15041035 37111521 PMC10142572 · DOI
  81. [87]Sheth T, Seshadri S, Prileszky T, Helgeson ME. Multiple nanoemulsions. Nat Rev Mater. 2020; 5(3): 214– 228. doi: 10.1038/s41578-019-0161-9 · DOI
  82. [88]Shah B. Microemulsion as a promising carrier for nose to brain delivery: journey since last decade. J Pharmac Invest. 2021; 2021: 1– 24.
  83. [89]Li M, Du C, Guo N, et al. Composition design and medical application of liposomes. Europ J Med Chemist. 2019; 164: 640– 653. doi: 10.1016/j.ejmech.2019.01.007 30640028 · DOI
  84. [90]Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Advan Drug Deliv Rev. 2021; 176: 113851. doi: 10.1016/j.addr.2021.113851 34224787 · DOI
  85. [91]Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. J Pharmaceut Investig. 2023; 53(1): 19– 33. doi: 10.1007/s40005-022-00607-6 PMC9761651 36568502 · DOI
  86. [92]Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019; 27(7): 742– 761. doi: 10.1080/1061186X.2018.1527337 30239255 · DOI
  87. [93]Briuglia M-L, Rotella C, McFarlane A, Lamprou DA. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Translat Res. 2015; 5(3): 231– 242. doi: 10.1007/s13346-015-0220-8 25787731 · DOI
  88. [94]Ryu S, Jin M, Lee H-K, Wang M-H, Baek J-S, Cho C-W. Effects of lipid nanoparticles on physicochemical properties, cellular uptake, and lymphatic uptake of 6-methoxyflavone. J Pharmaceut Investig. 2022; 52(2): 233– 241. doi: 10.1007/s40005-021-00557-5 · DOI
  89. [95]Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Engin. 2016; 68: 982– 994. doi: 10.1016/j.msec.2016.05.119 27524099 · DOI
  90. [96]Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019; 51: 255– 267. doi: 10.1016/j.jddst.2019.02.017 · DOI
  91. [97]Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Europ J Pharmac Biopharm. 2018; 133: 285– 308. doi: 10.1016/j.ejpb.2018.10.017 30463794 · DOI
  92. [98]Abouhussein DM, Khattab A, Bayoumi NA, Mahmoud AF, Sakr TM. Brain targeted rivastigmine mucoadhesive thermosensitive in situ gel: optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J Drug Deliv Sci Technol. 2018; 43: 129– 140. doi: 10.1016/j.jddst.2017.09.021 · DOI
  93. [99]Verekar RR, Gurav SS, Bolmal U. Thermosensitive mucoadhesive in situ gel for intranasal delivery of Almotriptan malate: formulation, characterization, and evaluation. J Drug Deliv Sci Technol. 2020; 58: 101778. doi: 10.1016/j.jddst.2020.101778 · DOI
  94. [100]Gadhave D, Khot S, Tupe S, et al. Nose-to-brain delivery of octreotide acetate in situ gel for pituitary adenoma: pharmacological and in vitro cytotoxicity studies. Internat J Pharmac. 2022; 629: 122372. doi: 10.1016/j.ijpharm.2022.122372 36351503 · DOI
  95. [101]Gholizadeh H, Messerotti E, Pozzoli M, et al. Application of a thermosensitive in situ gel of chitosan-based nasal spray loaded with tranexamic acid for localised treatment of nasal wounds. AAPS Pharm Sci Tech. 2019; 20(7): 299. doi: 10.1208/s12249-019-1517-6 31482286 · DOI
  96. [102]Nair AB, Chaudhary S, Shah H, et al. Intranasal delivery of darunavir-loaded mucoadhesive in situ gel: experimental design, in vitro evaluation, and pharmacokinetic studies. Gels. 2022; 8(6): 342. doi: 10.3390/gels8060342 35735686 PMC9223067 · DOI
  97. [103]Wang Q, Wong C-H, Chan HE, Lee W-Y, Zuo Z. Statistical design of experiment (DoE) based development and optimization of DB213 in situ thermosensitive gel for intranasal delivery. Internat J Pharmac. 2018; 539(1–2): 50– 57. doi: 10.1016/j.ijpharm.2018.01.032 29366939 · DOI
  98. [104]Thakkar H, Vaghela D, Patel BP. Brain targeted intranasal in-situ gelling spray of paroxetine: formulation, characterization and in-vivo evaluation. J Drug Deliv Sci Technol. 2021; 62: 102317. doi: 10.1016/j.jddst.2020.102317 · DOI
  99. [105]Nafee N, Ameen AER, Abdallah OY. Patient-friendly, olfactory-targeted, stimuli-responsive hydrogels for cerebral degenerative disorders ensured > 400% brain targeting efficiency in rats. AAPS Pharm Sci Tech. 2020; 22(1): 6. doi: 10.1208/s12249-020-01872-0 33222021 · DOI
  100. [106]Thakkar JH, Prajapati ST. Formulation development and characterization of in-situ gel of rizatriptan benzoate for intranasal delivery. J Drug Deliv Ther. 2021; 11(1–s): 1– 6. doi: 10.22270/jddt.v11i1-s.4685 · DOI
  101. [107]Parashar P, Diwaker N, Kanoujia J, et al. In situ gel of lamotrigine for augmented brain delivery: development characterization and pharmacokinetic evaluation. J Pharm Investig. 2020; 50(1): 95– 105. doi: 10.1007/s40005-019-00436-0 · DOI
  102. [108]Swamy N, Abbas Z. Mucoadhesive in situ gels as nasal drug delivery systems: an overview. Asian J Pharm Sci. 2012; 7: 3.
  103. [109]Karavasili C, Fatouros DG. Smart materials: in situ gel-forming systems for nasal delivery. Drug Discov Today. 2016; 21(1): 157– 166. doi: 10.1016/j.drudis.2015.10.016 26563428 · DOI
  104. [110]Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv. 2009; 6(5): 543– 552. doi: 10.1517/17425240902939135 19413461 · DOI
  105. [111]Costa CP, Barreiro S, Moreira JN, et al. In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN). Pharmaceuticals. 2021; 14(8): 711. doi: 10.3390/ph14080711 34451808 PMC8400558 · DOI
  106. [112]Gao M, Shen X, Mao S. Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays. J Pharm Investig. 2020; 50(3): 251– 259. doi: 10.1007/s40005-020-00482-z · DOI
  107. [113]Nižić L, Ugrina I, Špoljarić D, et al. Innovative sprayable in situ gelling fluticasone suspension: development and optimization of nasal deposition. Int J Pharm. 2019; 563: 445– 456. doi: 10.1016/j.ijpharm.2019.04.015 30965121 · DOI
  108. [114]Castile J, Cheng Y-H, Simmons B, Perelman M, Smith A, Watts P. Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip. Drug Dev Ind Pharm. 2013; 39(5): 816– 824. doi: 10.3109/03639045.2012.707210 22803832 PMC3619451 · DOI
  109. [115]Perkušić M, Nižić Nodilo L, Ugrina I, et al. Chitosan-based thermogelling system for nose-to-brain donepezil delivery: optimising formulation properties and nasal deposition profile. Pharmaceutics. 2023; 15(6): 1660. doi: 10.3390/pharmaceutics15061660 37376108 PMC10302257 · DOI
  110. [116]Li X, Du L, Chen X, et al. Nasal delivery of analgesic ketorolac tromethamine thermo-and ion-sensitive in situ hydrogels. Int J Pharm. 2015; 489(1–2): 252– 260. doi: 10.1016/j.ijpharm.2015.05.009 25957699 · DOI
  111. [117]Saito S, Ainai A, Suzuki T, et al. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine. Vaccine. 2016; 34(9): 1201– 1207. doi: 10.1016/j.vaccine.2016.01.020 26802605 · DOI
  112. [119]Chen Y, Cheng G, Hu R, et al. A nasal temperature and pH dual-responsive in situ gel delivery system based on microemulsion of huperzine A: formulation, evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech. 2019; 20(7): 301. doi: 10.1208/s12249-019-1513-x 31485857 · DOI
  113. [120]Qu Y, Li A, Ma L, et al. Nose-to-brain delivery of disulfiram nanoemulsion in situ gel formulation for glioblastoma targeting therapy. Int J Pharm. 2021; 597: 120250. doi: 10.1016/j.ijpharm.2021.120250 33486040 · DOI
  114. [121]Cunha S, Swedrowska M, Bellahnid Y, et al. Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. Int J Pharm. 2022; 620: 121720. doi: 10.1016/j.ijpharm.2022.121720 35413397 · DOI
  115. [122]Tan MS, Pandey P, Lohman R-J, Falconer JR, Siskind DJ, Parekh HS. Fabrication and characterization of clozapine nanoemulsion sol-gel for intranasal administration. Mol Pharm. 2022; 19(11): 4055– 4066. doi: 10.1021/acs.molpharmaceut.2c00513 36149013 · DOI
  116. [123]Gadhave D, Tupe S, Tagalpallewar A, Gorain B, Choudhury H, Kokare C. Nose-to-brain delivery of amisulpride-loaded lipid-based poloxamer-gellan gum nanoemulgel: in vitro and in vivo pharmacological studies. Int J Pharm. 2021; 607: 121050. doi: 10.1016/j.ijpharm.2021.121050 34454028 · DOI
  117. [124]Nair AB, Chaudhary S, Jacob S, et al. Intranasal administration of dolutegravir-loaded nanoemulsion-based in situ gel for enhanced bioavailability and direct brain targeting. Gels. 2023; 9(2): 130. doi: 10.3390/gels9020130 36826300 PMC9956165 · DOI
  118. [125]Mura P, Mennini N, Nativi C, Richichi B. In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin. Eur J Pharm Biopharm. 2018; 122: 54– 61. doi: 10.1016/j.ejpb.2017.10.008 29032194 · DOI
  119. [126]Rajput A, Butani S. Donepezil HCl liposomes: development, characterization, cytotoxicity, and pharmacokinetic study. AAPS PharmSciTech. 2022; 23(2): 74. doi: 10.1208/s12249-022-02209-9 35149912 · DOI
  120. [127]El-Shenawy AA, Mahmoud RA, Mahmoud EA, Mohamed MS. Intranasal in situ gel of apixaban-loaded nanoethosomes: preparation, optimization, and in vivo evaluation. AAPS PharmSciTech. 2021; 22(4): 147. doi: 10.1208/s12249-021-02020-y 33948767 · DOI
  121. [128]Ourani-Pourdashti S, Mirzaei E, Heidari R, Ashrafi H, Azadi A. Preparation and evaluation of niosomal chitosan-based in situ gel formulation for direct nose-to-brain methotrexate delivery. Int J Biol Macromol. 2022; 213: 1115– 1126. doi: 10.1016/j.ijbiomac.2022.06.031 35691430 · DOI
  122. [129]Fahmy UA, Badr-Eldin SM, Ahmed OA, et al. Intranasal niosomal in situ gel as a promising approach for enhancing flibanserin bioavailability and brain delivery: in vitro optimization and ex vivo/in vivo evaluation. Pharmaceutics. 2020; 12(6): 485. doi: 10.3390/pharmaceutics12060485 32471119 PMC7356232 · DOI
  123. [130]Abdelnabi DM, Abdallah MH, Elghamry HA. Buspirone hydrochloride loaded in situ nanovesicular gel as an anxiolytic nasal drug delivery system: in vitro and animal studies. AAPS PharmSciTech. 2019; 20(3): 134. doi: 10.1208/s12249-018-1211-0 30830481 · DOI
  124. [131]Taymouri S, Shahnamnia S, Mesripour A, Varshosaz J. In vitro and in vivo evaluation of an ionic sensitive in situ gel containing nanotransfersomes for aripiprazole nasal delivery. Pharm Dev Technol. 2021; 26(8): 867– 879. doi: 10.1080/10837450.2021.1948571 34193009 · DOI
  125. [132]ElShagea HN, Makar RR, Salama AH, Elkasabgy NA, Basalious EB. Investigating the targeting power to brain tissues of intranasal rasagiline mesylate-loaded transferosomal in situ gel for efficient treatment of Parkinson’s disease. Pharmaceutics. 2023; 15(2): 533. doi: 10.3390/pharmaceutics15020533 36839855 PMC9967009 · DOI
  126. [133]Salem HF, Kharshoum RM, Abou-Taleb HA, Naguib DM. Nanosized transferosome-based intranasal in situ gel for brain targeting of resveratrol: formulation, optimization, in vitro evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech. 2019; 20(5): 181. doi: 10.1208/s12249-019-1353-8 31049748 · DOI
  127. [134]Uppuluri CT, Ravi PR, Dalvi AV. Design, optimization and pharmacokinetic evaluation of piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson’s disease. Int J Pharm. 2021; 606: 120881. doi: 10.1016/j.ijpharm.2021.120881 34273426 · DOI
  128. [135]Agrawal M, Pradhan M, Singhvi G, Patel R, Alexander A, Alexander A. Thermoresponsive in situ gel of curcumin loaded solid lipid nanoparticle: design, optimization and in vitro characterization. J Drug Deliv Sci Technol. 2022; 71: 103376. doi: 10.1016/j.jddst.2022.103376 · DOI
  129. [136]Abou Youssef NAH, Kassem AA, Farid RM, Ismail FA, Magda Abd Elsamea EM, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm. 2018; 548(1): 609– 624. doi: 10.1016/j.ijpharm.2018.07.014 30033394 · DOI
  130. [137]Sun Y, Li L, Xie H, et al. Primary studies on construction and evaluation of ion-sensitive in situ gel loaded with paeonol-solid lipid nanoparticles for intranasal drug delivery. Int J Nanomed. 2020; Volume 15: 3137– 3160. doi: 10.2147/IJN.S247935 PMC7210040 32440115 · DOI
  131. [138]Rajput AP, Butani SB. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol. 2019; 51: 214– 223. doi: 10.1016/j.jddst.2019.01.040 · DOI
  132. [139]Gadhave D, Rasal N, sonawane R, Sekar M, Kokare C. Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: pharmacological and in vitro cytotoxicity studies. Int J Biol Macromol. 2021; 167: 906– 920. doi: 10.1016/j.ijbiomac.2020.11.047 33186648 · DOI · Paper page
  133. [140]Taymouri S, Minaiyan M, Ebrahimi F, Tavakoli N. In-vitro and in-vivo evaluation of chitosan-based thermosensitive gel containing lorazepam NLCs for the treatment of status epilepticus. IET Nanobiotechnol. 2020; 14(2): 148– 154. doi: 10.1049/iet-nbt.2019.0156 32433032 PMC8676653 · DOI
  134. [141]Tripathi D, Sonar PK, Parashar P, Chaudhary SK, Upadhyay S, Saraf SK. Augmented brain delivery of cinnarizine through nanostructured lipid carriers loaded in situ gel: in vitro and pharmacokinetic evaluation. BioNanoScience. 2021; 11(1): 159– 171. doi: 10.1007/s12668-020-00821-2 · DOI
  135. [142]Fahmy UA, Ahmed OA, Badr-Eldin SM, et al. Optimized nanostructured lipid carriers integrated into in situ nasal gel for enhancing brain delivery of flibanserin. Int J Nanomed. 2020; Volume 15: 5253– 5264. doi: 10.2147/IJN.S258791 PMC7386805 32801690 · DOI
  136. [143]Rajput A, Bariya A, Allam A, Othman S, Butani SB. In situ nanostructured hydrogel of resveratrol for brain targeting: in vitro-in vivo characterization. Drug Deliv Transl Res. 2018; 8(5): 1460– 1470. doi: 10.1007/s13346-018-0540-6 29785574 · DOI
  137. [144]Abbas H, Refai H, El Sayed N. Superparamagnetic iron oxide-loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of clonazepam. J Pharm Sci. 2018; 107(8): 2119– 2127. doi: 10.1016/j.xphs.2018.04.007 29665379 · DOI
  138. [145]Butani S. Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil. Asian J Pharm. 2018; 12(04): 293– 302.
  139. [146]Matarazzo AP, Elisei LMS, Carvalho FC, et al. Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain. Eur J Pharm Sci. 2021; 159: 105698. doi: 10.1016/j.ejps.2020.105698 33406408 · DOI
  140. [147]Deshkar SS, Jadhav MS, Shirolkar SV. Development of carbamazepine nanostructured lipid carrier loaded thermosensitive gel for intranasal delivery. Adv Pharm Bulletin. 2021; 11(1): 150– 162. doi: 10.34172/apb.2021.016 PMC7961220 33747862 · DOI
  141. [148]Paiva-Santos AC, Silva AL, Guerra C, et al. Ethosomes as nanocarriers for the development of skin delivery formulations. Pharm Res. 2021; 38(6): 947– 970. doi: 10.1007/s11095-021-03053-5 34036520 · DOI
  142. [149]Raghuvanshi A, Shah K, Dewangan HK. Ethosome as antigen delivery carrier: optimisation, evaluation and induction of immunological response via nasal route against hepatitis B. J Microencapsul. 2022; 39(4): 352– 363. doi: 10.1080/02652048.2022.2084169 35635238 · DOI
  143. [150]Natsheh H, Touitou E. Phospholipid vesicles for dermal/transdermal and nasal administration of active molecules: the effect of surfactants and alcohols on the fluidity of their lipid bilayers and penetration enhancement properties. Molecules. 2020; 25(13): 2959. doi: 10.3390/molecules25132959 32605117 PMC7412180 · DOI
  144. [151]Bhardwaj P, Tripathi P, Gupta R, Pandey S. Niosomes: a review on niosomal research in the last decade. J Drug Deliv Sci Technol. 2020; 56: 101581. doi: 10.1016/j.jddst.2020.101581 · DOI
  145. [152]Pires PC, Rodrigues M, Alves G, Santos AO. Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs. Pharmaceutics. 2022; 14(3): 588. doi: 10.3390/pharmaceutics14030588 35335964 PMC8955176 · DOI
  146. [153]Sastri KT, Gupta NV, Sharadha M, et al. Nanocarrier facilitated drug delivery to the brain through intranasal route: a promising approach to transcend bio-obstacles and alleviate neurodegenerative conditions. J Drug Deliv Sci Technol. 2022; 75: 103656. doi: 10.1016/j.jddst.2022.103656 · DOI
  147. [154]Chamanza R, Wright J. A review of the comparative anatomy, histology, physiology and pathology of the nasal cavity of rats, mice, dogs and non-human primates. Relevance to inhalation toxicology and human health risk assessment. J Comparat Pathol. 2015; 153(4): 287– 314. doi: 10.1016/j.jcpa.2015.08.009 26460093 · DOI
  148. [155]Zahir-Jouzdani F, Wolf JD, Atyabi F, Bernkop-Schnürch A. In situ gelling and mucoadhesive polymers: why do they need each other? Expert Opinion on Drug Deliv. 2018; 15(10): 1007– 1019. doi: 10.1080/17425247.2018.1517741 30173567 · DOI
  149. [157]Lim C, Koo J, Oh KT. Nanomedicine approaches for medulloblastoma therapy. J Pharmac Investig. 2023; 53(2): 213– 233. doi: 10.1007/s40005-022-00597-5 · DOI
  150. [158]Lee S-H, Kim J-K, Jee J-P, Jang D-J, Park Y-J, Kim J-E. Quality by Design (QbD) application for the pharmaceutical development process. J Pharmac Investig. 2022; 52(6): 649– 682. doi: 10.1007/s40005-022-00575-x · DOI
  151. [159]Cunha S, Costa CP, Moreira JN, Lobo JMS, Silva AC. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: a review. Nanomedicine. 2020; 28: 102206. doi: 10.1016/j.nano.2020.102206 32334097 · DOI
  152. [160]Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trend Biotechnol. 2009; 27(9): 546– 553. doi: 10.1016/j.tibtech.2009.06.006 19647883 · DOI
  153. [161]Soni G, Kale K, Shetty S, Gupta M, Yadav KS. Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer. Heliyon. 2020; 6(4): e03846. doi: 10.1016/j.heliyon.2020.e03846 32373744 PMC7193322 · DOI
  154. [162]Li J, Qiao Y, Wu Z. Nanosystem trends in drug delivery using quality-by-design concept. J Controll Rel. 2017; 256: 9– 18. doi: 10.1016/j.jconrel.2017.04.019 28414149 · DOI

Cited by

Sorted by citations

Authors
Koo, J., Lim, C., & Oh, K. T.
Affiliations
  • Chung-Ang University (KR)
  • CHA University (KR)
Corresponding author
Oh, Kyung Taek
ORCID
Venue
International Journal of Nanomedicine
Publisher
Informa UK Limited
Published
2024-02
Volume
Volume 19
Pages
1767-1807
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
DOI
10.2147/ijn.s439181
PMC
PMC10898487
OpenAlex
W4392111751
Cited by
174
References
7
Citations by year
2026: 95 · 2025: 62 · 2024: 17
FWCI
6.47
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • National Research Foundation
  • National Research Foundation of Korea (2022R1C1C2002949, 2021R1A2C2008519, 2022R1A5A6000760)
  • Ministry of Science and ICT, South Korea (2021R1A2C2008519, 2022R1A5A6000760, 2022R1C1C2002949)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
intranasal drug delivery, nose-to-brain delivery, blood-brain barrier, lipid nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, in situ gel, nasal drug absorption, brain drug delivery, quality by design
MeSH terms
Administration, Intranasal, Blood-Brain Barrier, Brain, Lipids, Liposomes, Nasal Mucosa, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review